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Summary
 
Recombinant-activating gene 2 (RAG-2
 
2/2
 
) T cell receptor–transgenic mice repeatedly in-
jected with the superantigen staphylococcal enterotoxin A entered a tolerant state in which
splenic CD4
 
1
 
 T cells produced little interleukin (IL)-2, interferon 
 
g
 
, or IL-4. This state resulted
from a combination of both clonal anergy and cytokine-mediated immunosuppression. The
anergy persisted for at least 3 wk and could be distinguished from the suppression by a decrease
in IL-2 production per cell, a block in the activation of early response kinases, and a failure to
 
be reversed with anti–transforming growth factor (TGF)-
 
b
 
.
 
 Full suppression lasted for only
1 wk and involved both IL-10 and TGF-
 
b
 
, but required additional unknown molecules for opti-
mal effect. These experiments show that complex in vivo interactions of multiple peripheral tol-
erance mechanisms can now be dissected at both the cellular and molecular levels.
Key words: CD4
 
1
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b
 
T
 
he task of eliminating autoreactive T cells is mediated in
part by central deletion in the thymus. For antigens that
are not present in the thymus, or not present in high enough
concentrations to effectively delete reactive T cells there,
several peripheral mechanisms exist to control unwanted T
cell activation (1). One mechanism, mimicked by the intro-
duction of high doses of antigen into mice, results in the ap-
parent deletion or clonal exhaustion of the T cells (2). Another
mechanism renders the T cells functionally unresponsive to
further antigenic stimulation. Unresponsive states of this type
have been achieved in animal model systems by injection
of a superantigen (3–6), in transgenic systems in which antigen
is expressed only on peripheral cells (7, 8), by transfer of trans-
genic T cells into nude (9) or normal mice (10) expressing
the antigen, and by transfer of transgenic T cells to normal an-
imals with initiation of a tolerizing immunization protocol of
intravenous antigen in saline (11). In addition to antigen, B7–
CTLA-4 interactions may contribute to the generation of an
unresponsive state in vivo (12). The unresponsive state gener-
ated in many of these systems resembles T cell clonal anergy,
originally discovered using CD4
 
1
 
 T cell clones (13), in which
an initial signal through the TCR in the absence of costimula-
tion results in the inability to produce IL-2 and subsequently
to proliferate. However, in other systems there appears to be
an initial activation stage before T cells become unresponsive,
as they have been shown to express activation markers and
undergo expansion (10, 14, 15). Therefore, the nature of
all of the processes that lead to the induction of T cell func-
tional unresponsiveness in vivo are not yet clear and may in-
volve several simultaneous but distinct molecular mechanisms.
Recent experiments have also suggested a possible role
for regulatory cytokines in the induction of peripheral T cell
unresponsiveness. Injection of superantigen into AND TCR
transgenic mice results in IFN-
 
g
 
 production by CD4
 
2
 
CD8
 
2
 
cells with subsequent deletion of CD4
 
1
 
 T cells (16). Pro-
duction of IL-10 by unresponsive CD4
 
1
 
 and CD8
 
1
 
 cells has
been shown in other model systems (10, 14). Superantigen
stimulation of V
 
b
 
 transgenic mice can result in high levels
of IL-10 in the serum, and the amount of IL-10 produced
by CD4
 
1
 
 T cells is inversely correlated with the amount of
IL-2 that they are able to make upon restimulation (6). IL-10
has been shown to have both a direct effect on IL-2 pro-
duction by human T cells (17) and an indirect effect by di-
minishing MHC class II and costimulatory molecule expres-
sion on the surface of APCs (18–20). However, in one
system, pretreatment of mice with neutralizing antibody be-
fore superantigen injection failed to restore IL-2 production,
indicating a correlative but not a causative role for IL-10 in
the induction/maintenance of T cell proliferative unrespon-
siveness in vivo (6). In addition to IL-10, TGF-
 
b
 
 has been
implicated as a regulatory cytokine produced by T cells found
at sites of chronic antigenic stimulation (21), and is thought
to contribute to the induction of oral tolerance (22) and the
immune deviation observed when antigen is injected into
the anterior chamber of the eye (23). TGF-
 
b
 
 is known to
block cell cycle progression (24) and may have a direct ef-
fect on expression of the IL-2 gene (25).
Long-term culture of spleen cells from DO11.10 TCR
transgenic mice in the presence of antigen and IL-10 can
produce an unresponsive state (26). The resulting CD4
 
1
 
 T 
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cells were initially considered to be anergic, because similar
cells isolated from human PBLs did not proliferate or pro-
duce IL-2 upon restimulation with antigen (27). In addition,
the upregulation of the IL-2R
 
a
 
 chain was blocked, indicat-
ing a more profound state of unresponsiveness, similar to that
which has been described in vivo for superantigen-induced
murine anergy (28). However, the human and mouse cell
lines were subsequently found to be suppressive for prolifera-
tion of naive T cells by secreting IL-10 and TGF-
 
b
 
. There-
fore, they were given a new name, Tr1 cells, which denotes
their suppressive capacity. Nonetheless, in this system, as in
most previously described systems, the molecular mecha-
nisms underlying the induced tolerant state were not clearly
delineated and the distinction between anergy and cytokine-
mediated suppression was not fully defined. For example,
was the effect of the suppression on the proliferation of naive
T cells the same mechanism as that which prevented the Tr1
cells from making IL-2?
In this paper, we establish an in vivo murine tolerance
model designed to address some of these issues using a CD4
 
1
 
TCR transgenic mouse on a RAG-2
 
2/2
 
 background. In this
system, peripheral T cells lose the ability to produce IL-2,
IL-4, and IFN-
 
g
 
 upon antigenic rechallenge after repeated
immunization with the superantigen staphylococcal entero-
toxin A (SEA).
 
1
 
 The IL-2 production defect resulted from
two distinct mechanisms: cytokine-mediated suppression and
clonal anergy. The suppressive mechanism, found in the
supernatant of antigen-stimulated SEA-treated spleen cells,
involved IL-10 and TGF-
 
b
 
, but clearly required an addi-
tional factor(s) for maximum effect. The suppression could
be distinguished from an underlying anergic mechanism at
both the cellular and molecular levels. The suppressive ef-
fect started to wane by day 6 after the last injection with
SEA, whereas the production of IL-2 on a per cell basis re-
mained consistently low until at least day 20. The decrease
in IL-2 production per cell was correlated with a diminished
activation of the early response kinases (ERKs) in response to
TCR stimulation, similar to what has been observed in T
cell clones rendered anergic (29, 30). Suppressive superna-
tants did not cause a block in ERK activation, and anti–
TGF-
 
b
 
 could not fully reverse the block in IL-2 produc-
tion, even at day 4, allowing us to identify the existence of
clonal anergy in the presence of cytokine-mediated sup-
pression. Thus, this model system appears to be well suited
for understanding the onset and interaction of multiple
molecular mechanisms of peripheral tolerance in vivo.
 
Materials and Methods
 
Mice and Immunization.
 
C57BL/6 TCR–Cyt 5C.C7-1 trans-
genic mice (37) were backcrossed multiple times to B10.A mice
in the NIAID contract facility at Taconic Farms, Inc. They were
 
then bred to B10.D2 RAG-2
 
2/2
 
 mice to introduce the Rag-2
 
2/2
 
mutation and made homozygous for B10.A, RAG-2
 
2/2
 
, and the
TCR transgene. This strain is referred to as B10.A/SgSnAi
TCR–Cyt 5C.C7-1 RAG-2
 
2/2
 
 and can be purchased from the
NIAID/Taconic Farms, Inc. exchange. The spleens of these ani-
mals are comprised of 40–50% CD4
 
1
 
 T cells and 1–2% CD8
 
1
 
 T
cells, all bearing the V
 
a
 
11/V
 
b
 
3 transgenic receptor. The remain-
der of the spleen is composed of NK1.1
 
1
 
 cells (20%, all of which
are TCR negative), macrophages (10%), and other hematopoietic
(CD45
 
1
 
) cells (15–20%). 6–12-wk-old mice were given three in-
traperitoneal injections of 1 
 
m
 
g of SEA (Toxin Technologies) in
PBS, or 100 
 
m
 
l of PBS alone at 4-d intervals and assayed at vari-
ous time points after the third injection. No LPS contamination
(
 
,
 
0.01 U/ml) was detected in the SEA preparations used, as
measured with the E-toxate kit (Sigma Chemical Co.).
 
T Cell Proliferation Assay.
 
Spleen cells (10
 
5
 
) were cultured
with 5 
 
3
 
 10
 
5
 
 irradiated (3,000 rads) T-depleted B10.A spleen
cells as APCs (38) and 1 
 
m
 
M pigeon cytochrome 
 
c
 
 (PCC) peptide
(amino acids 81–104, synthesized in the peptide synthesis facility,
NIAID, National Institutes of Health) in E/R medium (50% Ea-
gle’s Hank’s amino acids plus 50% RPMI 1640 medium [Biofluids,
Inc.]) supplemented with 10% FCS (Biofluids), 4 mM glutamine,
penicillin (200 
 
m
 
g/ml), streptomycin (200 
 
m
 
g/ml), gentamycin
(25 
 
m
 
g/ml), and 50 
 
m
 
M 
 
b
 
-ME, in flat-bottomed 96-well plates at
37
 
8
 
C, 5% CO
 
2
 
 (final vol 0.2 ml). After 48 h in culture, 100 
 
m
 
l of
supernatant was removed for cytokine assays. The wells were
then pulsed with 1 
 
m
 
Ci [
 
3
 
H]thymidine (6.7 Ci/mmol; ICN) and
harvested 16 h later onto glass fiber filters using a 96-well cell
harvester (Brandel). Incorporated [
 
3
 
H]thymidine was measured
by scintillation counting in a Betaplate 1205 detector (Wallac). In
experiments that examined the effect of supernatants on T cell
proliferation, the supernatant (50 
 
m
 
l) was added at a 1:3 vol ratio
with the final vol kept at 0.2 ml.
 
Limiting Dilution Analysis.
 
Total spleen cells were cultured at
various numbers with 4,000 PCC peptide–pulsed dendritic cells.
Dendritic cell-enriched populations were isolated as previously
described (39, 40). In brief, B10.A spleen cells were allowed to
adhere to plastic petri dishes (Falcon 3025, Becton Dickinson) for
2 h, washed, and cultured overnight at 37
 
8
 
C, 5% CO
 
2
 
 in the
presence of 1 ng/ml GM-CSF (PharMingen) with or without 1 
 
m
 
M
PCC peptide. The next day, nonadherent cells were collected,
spun through a 70% Percoll gradient, washed twice with E/R
medium, and put into culture with the responding spleen cells in
96-well U-bottomed plates (final vol 0.1 ml). After 48 h the
plates were frozen, thawed, and 1,000 CTL-L (obtained from
American Type Culture Collection) cells were added per well.
The plates were then incubated at 37
 
8
 
C, 5% CO
 
2
 
 for 16 h. Fi-
nally, the plates were pulsed with 1 
 
m
 
Ci [
 
3
 
H]thymidine and har-
vested 6 h later, as described above.
 
Cytokine ELISA and Bioassay.
 
The IL-2–dependent indicator
cell line CTL-L was used to quantitate the IL-2 content of cul-
ture supernatants. CTL-L cells were cultured at 1,000/well with
various dilutions of culture supernatants or with rIL-2 (PharMin-
gen) for a standard curve. IL-2 concentration in units per millili-
ter was determined using an algorithm to fit the data to a logistic
equation as previously described (41). The CTL-L cells did not
show any decreased response to 10 U/ml of IL-2 in the presence
of IL-10–, TGF-
 
b
 
–, or SEA-treated cell culture supernatants.
IL-10 and IFN-
 
g
 
 concentrations in culture supernatants were de-
termined by sandwich ELISA (Endogen). Total and acid-activated
TGF-
 
b
 
1 and 2 concentrations were measured by the E
 
max
 
 ELISA
system, according to the manufacturer’s instructions (Promega).
 
Antibody Blocking Experiments.
 
Monoclonal mouse anti–TGF-
 
b
 
1
 
Abbreviations used in this paper:
 
 AP, alkaline phosphatase; C
 
T
 
, threshold
cycle number; ERK, early response kinase; E/R, 50% EHAA plus 50%
RPMI 1640; 6-FAM, 6-carboxyfluorescein; MAP, mitogen-activated pro-
tein; PCC, pigeon cytochrome 
 
c
 
; RAG-2
 
2/2
 
, recombinant activating
gene 2 knockout; RT, reverse transcriptase; SEA, staphylococcal entero-
toxin A. 
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antibody (specific for murine TGF-
 
b
 
1, 2, and 3) was purchased
from Genzyme Corp. Rat anti–mouse IL-10 (clone JE55-16E3),
rat anti–mouse IL-4 (clone 11B11), rat anti–mouse IFN-
 
g
 
 (clone
XMG 1.2), and purified polyclonal mouse IgG (12297D) were
purchased from PharMingen. Rabbit anti–mouse prostaglandin
(PG)E
 
2
 
 and PGF
 
2
 
a
 
 antibodies (the latter was used as an isotype and
specificity control) were purchased from PerSeptive Diagnostics.
The ability of the antibodies to block the effects of the cytokine in
proliferation assays was tested by adding the cytokine to indicator cell
lines with or without antibody and assaying for activity. For anti–
TGF-
 
b
 
 antibody, the ability to block the decrease in proliferation
of mink lung cells (a gift from Martijn Lolkema, LCMI, NIAID,
Bethesda, MD) in response to recombinant human TGF-
 
b
 
 (Gen-
zyme Corp.) was used. Anti–IL-10 antibody was assayed for the
ability to block the increase in proliferation of the IL-3–depen-
dent cell line MC/9 (a gift from Dr. Yugata Takata, Metabolism
Branch, National Cancer Institute, Frederick, MD) in response to
rIL-10 (PharMingen). Anti–IL-4 antibody was assayed for its
ability to block the growth of the IL-4 dependent cell line CT4.S
(obtained from Cyndy Watson, Laboratory of Immunology, NIH,
Bethesda, MD) in rIL-4 (PharMingen). Anti-PGE
 
2
 
 antibody was
assayed for the ability to block the decrease in proliferation of an-
tigen-stimulated spleen cells from B10.A TCR–Cyt 5C.C7-1
Rag-2
 
2/2
 
 mice that is caused by PGE
 
2
 
 (Alexis Corp.). Anti–IFN-
 
g
 
and anti–TNF-
 
a
 
 antibodies were used at 10 
 
m
 
g/ml, a concentra-
tion previously shown to block the effects of IFN-
 
g
 
 (16) in spleen
cell cultures. Recombinant mouse IL-10 was purchased from
PharMingen and recombinant human TGF-
 
b
 
1 and 2 were gifts
from Drs. Anita Roberts and Nan Roche (Laboratory of Chemo-
prevention, NCI, NIH, Bethesda, MD).
 
Quantitative PCR.
 
10
 
5
 
 spleen cells from PBS- or SEA-treated
mice were cultured in E/R medium in the presence of 5 
 
3
 
 10
 
5
 
T-depleted, irradiated spleen cells in 6-well plates for 24 h at
37
 
8
 
C in the presence of 3 
 
m
 
g/ml of anti-CD3 (2C11; reference
42) and a 1:1,000 dilution of anti-CD28 ascites (43). The cells
were then scraped from the wells and total RNA was extracted
using the RNeasy kit (Qiagen). Reverse transcriptase (RT)-PCR
reactions were coupled and performed in the same tube using
10–100 ng of total RNA in 1
 
3
 
 TaqMan EZ buffer, 2.5 mM
manganese acetate, 300 
 
m
 
M of each dNTP, and 100 U/ml of rTth
DNA polymerase in a total vol of 25 
 
m
 
l (PE Applied Biosystems).
The RT step was primed with the IL-2–specific back primer
5
 
9
 
-TTTCAATTCTGTGGCCTGCTT –3
 
9
 
 and was carried out
at 58
 
8
 
C for 30 min, preceded by a 75
 
8
 
C for 10 min denaturation
step. Amplification of the product was accomplished through the
use of the IL-2–specific forward primer 5
 
9
 
-GCACCTGGAGCA-
GCTGTTG-3
 
9
 
 and the same IL-2–specific back primer as used
in the RT step. The back primer spans an exon/intron junction
and will not amplify genomic DNA or unspliced RNA. The PCR
step consisted of 40 cycles of 94
 
8
 
C for 15 s 
 
®
 
 
 
58
 
8
 
C for 60 s pre-
ceded by an initial 95
 
8
 
C for 1 min denaturation step. Detection
of the amplicon was achieved by dequenching of a 6-carboxyfluo-
rescein (6-FAM)–labeled IL-2–specific probe (5
 
9
 
-ACCTACAG-
GAGCTCCTGAGCAGGATG-3
 
9
 
) during amplification and
measurement of the released fluorescence with an ABI-7700 Se-
quence Detection System (PE Applied Biosystems) (44). H-2K
mRNA was used as an internal reference. The RT step was
primed with the H-2K–specific back primer 5
 
9
 
-GGGCTCAG-
GCAGCC-3
 
9
 
. PCR was carried out with the H-2K–specific for-
ward primer 5
 
9
 
-AGAAGTGGGCATCTGTGG-3
 
9
 
 and the same
H-2K–specific back primer as used in the RT step. Detection of
the amplicon was achieved by dequenching of a 6-FAM–labeled
H-2K–specific probe (5
 
9
 
-TTGGGAAGGAGCAGTATTACACA-
 
TGC-3
 
9
 
), which only amplified cytoplasmic mRNA. RT-PCR
reaction conditions were exactly the same as those described
above. Standard curves were generated for H-2K and IL-2 mRNAs
with total RNA from A.E7 T cells stimulated with anti-TCR
(H57; reference 45) and costimulated with anti-CD28 for 4 h.
The log of the total RNA (nanograms) plotted versus the thresh-
old cycle number (CT) is a linear function; where the CT is defined
as the amplification cycle number at which the fluorescence
emitted is .10 SD above the average baseline fluorescence (usu-
ally the amount of fluorescence measured between cycles 3 and
15). The relative amount of mRNA in the unknown samples was
determined from the standard curves. All samples were assayed in
triplicate and CT standard deviations were ,20%.
FACS® Analysis. To induce IL-2Ra expression, total spleen
cells from PBS- or SEA-treated mice were put into 6-well plates
previously coated with 3 mg/ml of anti-CD3 antibody for 4 h at
48C. A 1:1,000 dilution of anti-CD28 ascites was added and the
cells were cultured for 24 h at 378C with 5% CO2. Control wells
were coated with PBS. The cells were then scraped from the
plates and 106 cells were incubated for 30 min in FACS buffer
(PBS plus 1% BSA plus 0.01% sodium azide) with 5 mg/ml of
anti-CD4–FITC (Caltag) and 5 mg/ml of anti-CD25–PE (Phar-
Mingen). Cells were gated on CD4 and analyzed for the expres-
sion of CD25. Before labeling with specific antibodies, FcRs
were blocked with 10 mg/ml of 2.4G2 antibody (PharMingen).
After two washes, the cells were analyzed on a FACScalibur®
(Becton Dickinson). Mean fluorescence intensities were compared
between stimulated and unstimulated cells.
ERK Activation Assay and Immunoblotting. Total spleen cells
(7 3 106/well) were washed, resuspended in 50 ml of E/R medium
(serum-free), and incubated in the presence of medium alone or
anti-CD3 antibody–coated 24-well plates (10 mg/ml) at 378C for
various time points. In some experiments, CD81 cells were first
depleted using rat anti–mouse CD8 antibody (clone 53-6.7; Phar-
Mingen) and anti–rat IgG coupled to dynabeads (Dynal, Inc.).
The cells were lysed in the wells with 50 ml of 23 Tris-Glycine
SDS sample buffer (Novel Experimental Technologies) plus 1 mM
dithiothreitol, and the cellular DNA was sheared by passage
through a 25-gauge needle fitted to a 1 cm3 tuberculin syringe.
Protein concentrations were determined with the BCA Protein
Assay (Pierce), and 30 mg of total protein was analyzed from each
sample using SDS 14% PAGE gels.The proteins were transferred
to nitrocellulose and blots were probed with 1.4 mg/ml of an-
tiphospho-ERK antibody (E-4, Santa Cruz Biotechnology), fol-
lowed by anti–mouse IgG–alkaline phosphatase 100 ng/ml (Santa
Cruz Biotechnology) and visualized with ECF substrate (Amer-
sham). For total ERK 112 determination, blots were stripped in
buffer (100 mM 2-ME, 2% SDS, 62.5 mM Tris-HCl, pH 6.7) at
508C for 30 min, washed, and reblotted with anti-ERK 1/2 anti-
serum (Upstate Biotechnology, Inc.) at 1 mg/ml followed by
anti–rabbit IgG–alkaline phosphatase. For supernatant experiments,
supernatants obtained from stimulated spleen cell cultures of SEA-
treated animals from day 4 after the third injection were incubated
with naive spleen cells for various times at a 1:4 dilution in serum-
free E/R medium at 378C. The cells and supernatant were then
transferred to anti-CD3–coated plates and stimulated as above.
Results
Repeated Immunization with SEA Results in Decreased Spleen
Cell Proliferation and IL-2 Production upon Restimulation with
Peptide. Spleen cells from B10.A TCR–Cyt 5C.C7-156 Anergy and Suppression In Vivo
RAG2/2 mice injected intraperitoneally three times with 1 mg
of SEA at 4-d intervals exhibit a profound decrease in pro-
liferation when restimulated in culture for 48 h with the
81–104 peptide of PCC and APCs. The proliferative re-
sponse is decreased fivefold by day 4 after immunization,
and begins to increase slightly thereafter, reaching 60% of
normal by day 20 (Fig. 1 A). Proliferation was greatest at
1 mM peptide, and concentrations of up to 1 mM peptide
did not increase the response (data not shown). The decrease
in proliferation at day 4 was paralleled by a decrease in IL-2
production. It was 100-fold less than the IL-2 production
by control spleen cells and only returned to 8% of normal by
day 20 (Fig. 1 A). Addition of 10 U/ml of IL-2 during the
culture period did not augment the proliferative response,
suggesting that responsiveness to IL-2 was also impaired.
Although it was clear that less IL-2 was detected in the
supernatants of SEA-treated spleen cells, the remote possi-
bility remained that IL-2 was being produced but con-
sumed at a high rate, and that proliferation was blocked by
another mechanism. To determine if the production of
IL-2 was also inhibited at the mRNA level, the amount of
IL-2 message was measured by quantitative RT-PCR. The
total amounts of H-2K mRNA detected were comparable
between stimulated and unstimulated SEA-treated and PBS-
treated control cells; however, when IL-2 message-specific
primers were used, there was 10,000-fold more IL-2 mRNA
amplified at 24 h from the PBS-immunized spleen cells
stimulated with the potent combination of anti-CD3 and
anti-CD28 than there was from the day 4 SEA-treated
spleen cells (Fig. 1 B). Only a small amount of product was
amplified from unstimulated cells obtained from either SEA-
treated or PBS-treated animals. At day 20, the difference
was less dramatic, but there was still nearly 100-fold more
IL-2 mRNA induced in the PBS-treated cells compared
with the SEA-treated cells upon stimulation with antigen
plus APCs (Fig. 1 B). One experiment at day 4 with anti-
gen plus APCs as the stimulus also showed little IL-2
mRNA in the SEA-treated cells (data not shown). Thus, the
profound decrease in IL-2 measured in the culture superna-
tants of SEA-treated spleen cells is a consequence of decreased
IL-2 production.
Because decreased responsiveness to IL-2 was observed
both at day 4 and at day 20 after the last injection, the level
of IL-2Ra was determined on the surface of anti-CD3–
and anti-CD28–stimulated CD41 cells from SEA- and PBS-
treated mice. At day 4, IL-2Ra chain upregulation was di-
minished on the SEA-treated spleen cells. Only 10% of the
SEA-treated cells expressed IL-2Ra, and the mean fluores-
cent intensity of the positive cells was 75% of the control
(Fig. 1 C). By day 20, however, the upregulation of IL-2Ra
had returned to near normal, even though the responsive-
ness to IL-2 was still impaired, suggesting that signal trans-
duction through the IL-2R might also be affected.
Limiting Dilution Analysis with Spleen Cells from SEA-treated
Mice Reveals a Prolonged Decrease in IL-2 Production at the Single
Cell Level. Spleen cells from SEA-treated animals were
plated at decreasing cell numbers (from 25 cells/well to
0.25 cell/well in twofold dilutions) and stimulated with
peptide-pulsed purified dendritic cells (4,000/well). The
amount of IL-2 produced per positive well was calculated
at limiting dilution, where it was estimated that #1 cell per
well had been plated. Cells from PBS-treated animals pro-
duced statistically significantly more IL-2 per cell than did
cells from SEA-treated mice (Fig. 2, A and C). The geo-
metric mean of the ratio of SEA- to PBS-treated cell responses
Figure 1. Spleen cells from SEA-treated B10.A TCR–Cyt 5C.C7-1
RAG-22/2 mice exhibit profound blocks in proliferation, IL-2 produc-
tion, and responsiveness to IL-2. (A) 105 spleen cells isolated from SEA-
and PBS-injected mice were stimulated with 1 mM PCC peptide in the
presence of 5 3 105 T-depleted, irradiated B10.A spleen cells for 48 h. In
some groups, IL-2 (10 U/ml) was added in the beginning to assess re-
sponsiveness to this cytokine. Culture supernatants were harvested, the
cultures were assayed for proliferation by [3H]thymidine incorporation,
and the amount of IL-2 in the supernatant was measured by a CTL-L as-
say in the groups without added IL-2. Data represent the mean 6 SD of
11 separate experiments and are expressed as a percentage of the PBS
control. (B) Total mRNA was isolated from 106 spleen cells from SEA-
treated or control PBS-treated animals after stimulation with a combina-
tion of anti-CD3/anti-CD28 (day 4), antigen plus APCs (day 20), or no
stimulation (day 4 and day 20). The amount of IL-2 message was deter-
mined by quantitative PCR analysis using specific primers (see Materials
and Methods). H-2K mRNA was amplified as a control for the amount
of RNA present in the reaction mixture. (C) Spleen cells were stimulated
for 24 h with plate-bound anti-CD3 (3 mg) plus anti-CD28 (1:1,000 di-
lution ascites) antibodies, and then analyzed by FACS®. Cells were gated
on the CD41 population and analyzed for IL-2Ra (CD25) expression.
Data shown is representative of four separate experiments.57 Miller et al.
was 0.40 3/4 (1.15), i.e., the average responsive SEA-
treated cell produced 2.5-fold lower amounts of IL-2 upon
stimulation. Because of this difference in the amount of IL-2
produced per cell, the frequency of responsive cells in the
SEA-treated group could not be directly compared with
the PBS-treated group (found to be one out of six, data not
shown). However, the different SEA-treated groups could
be compared among themselves, as almost all produced the
same low amount of IL-2 per cell. Using the data from ex-
periment 1, the measured frequency of IL-2 producers was
lowest at day 4 (1 out of 34), increased twofold by day 5,
and then rose to 1 in 10 cells by day 20 (Fig. 2 B). The per-
centages of CD41 cells in the spleen were similar from day
4 to 6 (18–23%). However, by day 20 the percentage had
returned to normal (40%). Thus, the decreased frequency
of responding cells slowly reverses with time, but the IL-2
response of these cells remains low.
Spleen Cells from SEA-treated Mice Can Suppress IL-2 Produc-
tion from Naive Spleen Cells Stimulated with Peptide plus APCs.
105 or 5 3 104 spleen cells from SEA-treated mice were
mixed at a 1:1 ratio with PBS-treated control spleen cells in
culture with peptide plus APCs to determine if a suppres-
sive effect on IL-2 production was operative in the culture
system. SEA-treated spleen cells almost completely abro-
gated IL-2 production by peptide-stimulated PBS control
spleen cells (Fig. 3 A) or naive spleen cells (data not shown).
In the experiment with 105 cells, the suppression was mea-
sured as a .500–1,000-fold decrease in IL-2 production
from day 4 to 6, but then waned to only 3–10-fold by day
20 after immunization (Fig. 3 A). The effect was also seen
at decreasing cell numbers: as few as 6,000 SEA-treated
spleen cells per well still gave significant suppression (data
not shown).
Purified CD41 Cells from SEA-treated Mice Mediate the Sup-
pressive Effect of Stimulated Naive Spleen Cells on IL-2 Produc-
tion. Several different cell populations that could contribute
to the observed block in IL-2 production and proliferation
are present in the spleens of SEA-treated mice. To deter-
mine whether the CD41 subpopulation alone could effect
suppression of IL-2 production in stimulated naive spleen
cells, spleen cells from SEA-treated mice were stained with
anti-CD4 antibody and were FACS® sorted to .99% pu-
rity (Fig. 3 B). Purified CD41 cells from SEA-treated ani-
mals proliferated poorly to the 81–104 PCC peptide (data
not shown) and made little IL-2 (Fig. 3 B). When the puri-
fied CD41 cells were mixed in culture with either total
spleen cells (data not shown) or purified CD41 T cells from
PBS-immunized control animals (Fig. 3 B), IL-2 produc-
tion was suppressed to the same level as seen with total
SEA-treated spleen cells.
A small (z2%) population of CD41Va112 cells is present
in the spleens of SEA-treated animals. To determine if it was
only this population of cells that was mediating the sup-
pressive effect, spleen cells from SEA-treated mice were
double-stained for Va11 and CD4 and were FACS® sorted
to .99% purity. The CD41Va111 T cells were able to
suppress IL-2 production from stimulated total or CD41
FACS®-purified spleen cell populations (data not shown).
CD81 T cells were also purified by FACS® sorting from
SEA-treated animals (Fig. 3 B). In SEA-treated B10.A
TCR–Cyt 5C.C7-1 RAG-22/2 mice, the initially very small
CD81 population can increase to 30% of total spleen cells
by day 4 after the third injection of SEA (data not shown).
Purified CD81 cells at this time point do not proliferate in
response to stimulation with SEA or 81–104 peptide plus
APCs, but show a small proliferative response in the pres-
Figure 2. The frequency of
IL-2–producing cells in the
spleens of SEA-treated mice in-
creases over time after injection
of SEA, whereas the amount of
IL-2 produced per cell remains
low. (A) Spleen cells from SEA-
treated mice were plated at de-
creasing cell numbers with 4,000
purified dendritic cells and 1 mM
PCC peptide in 96-well plates.
After 48 h in culture, the plates
were frozen, then thawed, and
1,000 CTL-L cells were added
to the wells. The wells were
pulsed with [3H]thymidine and
assayed for IL-2 production (thy-
midine incorporation) 6 h later.
The amount of IL-2 on a per cell basis per time point was assayed by us-
ing the dilution of cells at which 37% (or more) of the wells were nega-
tive (plating efficiency of 1 cell per well) and plotting the cpm per well.
Results from two separate experiments are shown. (B) The frequency of
IL-2–producing cells per well is shown by plotting the number of cells
per well against the logarithm of the fraction of nonresponding wells.
This analysis was done on the data in experiment 1 shown in A. (C) Val-
ues represent mean 6 SEM from the limiting dilution analysis in A, at a
point where one cell or less per well was plated (see Materials and Meth-
ods). The asterisk denotes a statistically significant difference from PBS
controls (P , 0.05) by analysis of variance.58 Anergy and Suppression In Vivo
ence of 10 U/ml IL-2 (data not shown). These cells also fail
to make IL-2 when stimulated with antigen plus APCs
(Fig. 3 B). Nonetheless, coculturing them with purified
CD41 spleen cells from PBS-treated mice did not result in
significant suppression of IL-2 production (Fig. 3 B). Al-
though a role for CD81 T cells in the induction of the un-
responsiveness in the CD41 T cells after the first or second
injection in vivo has not been be ruled out, it appears that
the CD81 population is not contributing in vitro to the
suppressive effect on IL-2 production from stimulated naive
spleen cells seen after three injections of superantigen.
Supernatants from Cultures of Stimulated SEA-treated Spleen
Cells Are Able to Suppress IL-2 Production from Stimulated Na-
ive Spleen Cells, and this Effect Can Be Blocked with Antibodies
against TGF-b and IL-10. To determine whether secreted
factors were responsible for the suppressive effect on IL-2
production, supernatants from stimulated cultures of SEA-
treated spleen cells were added at a 1:4 dilution to cultures
of naive spleen cells stimulated with 81–104 peptide plus
APCs. At day 4 after the last immunization with SEA, the
supernatants diminished IL-2 production from stimulated
naive spleen cells by 1,000-fold. The potency was similar at
day 5 and then began to decrease at day 6 (10-fold), and
was not detected at all at day 20 (Fig. 4 A). In other exper-
iments the suppression at the day 4 time point was only 10–
30-fold. The magnitude of the suppression correlated with
how long the supernatant was stored, even though frozen.
To determine which molecules might be causing the
suppression and which cell populations were responsible for
their production, cell culture supernatants from stimulated,
purified CD41 and CD81 cell populations were tested for
IL-10, TGF-b, IL-4, and IFN-g production by ELISA assay.
Purified CD41 T cells from SEA-treated mice produced
large amounts (1,500 pg/ml) of IL-10, whereas purified
CD81 cells and both subsets from PBS-treated animals pro-
duced only small amounts (Table I). TGF-b is secreted in
both biologically active and inactive precursor forms. Bio-
logically active TGF-b, as recognized by the detecting an-
tibody, was barely seen above the limits of the sensitivity of
the ELISA assay (30 pg/ml) in the supernatants of stimu-
lated, purified, SEA-treated CD41 cells. After acid activa-
tion of the supernatants to convert any precursor TGF-b to
the form recognized by the detecting antibody, 400 pg/ml
of total TGF-b was detected in the supernatants of stimu-
lated, purified CD41 cells from the SEA-treated mice.
Nothing was detected from either the CD81 cells or both
subsets from PBS-treated animals. The presence of IL-4
could not be detected in the supernatants of stimulated
SEA-treated spleen cell cultures at any time point or in any
of the purified subpopulations, although it could be de-
tected if the mice had been immunized with PCC (data not
shown). In mice not carrying the RAG-22/2 gene–targeted
mutation, IL-4 production was detected in a limiting dilu-
tion assay with spleen cells from PBS-treated animals and
this production disappeared in spleen cells from SEA-
treated mice (data not shown). Similarly, in RAG-22/2
B10.A TCR–Cyt 5C.C7-1 mice, IFN-g was produced at
lower levels in purified CD41 and CD81 cells from SEA-
treated mice than in spleen cells from PBS-injected control
mice (Table I).
Thus, the CD41 population in the spleens of SEA-
treated animals produces significant amounts of at least one
cytokine, IL-10, that could contribute to the observed de-
Figure 3. CD41 spleen cells from SEA-treated animals can suppress
IL-2 production from stimulated naive spleen cells, and the effect dimin-
ishes with time. (A) 105 spleen cells alone from SEA-treated, PBS-treated,
or mixtures of 105 or 5 3 104 PBS-treated plus SEA-treated spleen cells,
were cultured with 1 mM PCC peptide in the presence of 5 3 105
T-depleted irradiated B10.A spleen cells for 48 h. Culture supernatants
were harvested and IL-2 production was measured by a CTL-L assay.
The experiment from day 4 was repeated 10 times, and those from days 5,
6, and 20 were repeated four times with similar results. (B) Spleen cells
from SEA- or PBS-treated mice were stained with anti-CD4 or anti-
CD8 antibodies and were FACS® sorted. Purified CD41 or CD81 T cells
(105) from SEA-treated mice were cultured with 105 purified CD41 T
cells from PBS-treated mice in the presence of 1 mM PCC peptide and
5 3 105 T-depleted, irradiated spleen cells for 48 h (purity shown at top).
Supernatants were then harvested and assayed for IL-2 production by
CTL-L assay. Results from mixtures using unfractionated cells are shown
for comparison. The CD41 and CD81 sorts are from separate experi-
ments. Each experiment was performed three times.59 Miller et al.
crease in proliferation and IL-2 production. The small amount
of TGF-b also turned out to be significant. The suppressive
effect of the supernatant could be partially blocked with an
antibody against IL-10, and completely blocked with an
anti–TGF-b antibody (Fig. 4 A). Antibodies against TNF-a
(data not shown), IFN-g, PGE2, an isotype control anti-
body (anti-PGF2a), or mouse IgG1 did not block the decrease
in IL-2 production observed in stimulated naive spleen cells
cultured with the supernatants.
However, the suppressive effect of the supernatants could
only partially be mimicked by the addition of recombinant
IL-10 and TGF-b (Table II). A significant suppressive effect
was seen only when both cytokines were added together.
TGF-b2 was always slightly more potent than TGF-b1. The
lowest dose of each cytokine that consistently created a
synergistic suppressive effect on IL-2 production was 1 ng
of IL-10 and 30–100 pg of TGF-b. Thus, it appears that
the concentrations of IL-10 and TGF-b measured in the
supernatants of stimulated, purified CD41 T cells from
SEA-treated mice could account for part of the observed
decrease in IL-2 production. On the other hand, the most
striking aspect of the data is that the combined effect of
these two cytokines was never able to mimic the enormous
suppression seen with the supernatants (Table II). In con-
Figure 4. The suppression mediated by the su-
pernatants can be blocked with antibodies to IL-10
and TGF-b; however, only anti–TGF-b antibody
can partially restore IL-2 production in cultures of
SEA-treated spleen cells. (A) 105 naive spleen cells
were cultured with 1 mM PCC peptide and 5 3
105 T-depleted, irradiated B10.A spleen cells for 48 h
in the presence of supernatant from stimulated cul-
tures of SEA-treated mice (1:3, vol/vol), and in the
presence or absence of the indicated antibodies at
10 mg/ml. The experiment is representative of
three performed. (B) Spleen cells (105) from SEA-
treated mice were cultured with 1 mM PCC pep-
tide and 5 3 105 irradiated, T-depleted B10.A spleen
cells for 48 h alone or with the indicated antibodies
at 10 mg/ml. Supernatants were then harvested and
IL-2 production was measured with a CTL-L assay.
The experiment was performed three times with
similar results.
Table I. Cytokine Secretion by Purified T Cell Populations from SEA-treated versus PBS-treated B10.A TCR–Cyt 5C.C7-1
Rag-22/2 Mice
CD41 T cells CD81 T cells
PBS-treated SEA-treated PBS-treated SEA-treated
IL-10 (pg/ml) 50 1,500 25 100
TGF-b (pg/ml) n.d. 30 n.d. n.d.
TGF-b (acid-activated, pg/ml) n.d. 400 n.d. n.d.
IL-4 (pg/ml) n.d. n.d. n.d. n.d.
IL-2 (U/ml) 94 0.06 72 0.05
IFN-g (U/ml) .10 1.25 .10 1.25
FACS®-sorted CD41 or CD81 T cells were stimulated for 48 h in the presence of PCC 81–104 peptide plus APCs. The supernatants were then re-
moved and measured for cytokine production by bioassay (for determination of units/milliliter IL-2) or ELISA. Data are representative of three sep-
arate experiments. n.d., not detectable.60 Anergy and Suppression In Vivo
trol experiments, addition of the supernatants had no effect
on viability or recovery of the stimulated naive spleen cells.
Thus, there appears to be one or more unknown compo-
nents in the supernatants that are also required for complete
suppression.
Only Anti-TGF-b Antibody Can Partially Reverse the Block
in IL-2 Production by Spleen Cells from SEA-treated Animals
upon Restimulation with Peptide plus APCs. Antibodies to
IL-10 and TGF-b were added to SEA-treated spleen cells
cultured alone to determine if these secreted factors were
also responsible for the block in IL-2 production by these
cells. Surprisingly, addition of anti–IL-10 did not signifi-
cantly affect the amount of IL-2 produced upon stimulation
with 81–104 PCC peptide plus APCs (Fig. 4 B). Anti–IFN-g
antibody, previously shown to block unresponsiveness by
interfering with SEA-induced apoptosis after one injection
of superantigen, (16) also had no effect. In contrast, anti–
TGF-b antibody increased IL-2 production 10-fold. None-
theless, the amount of IL-2 produced was still 30-fold less
than that produced by the PBS control cells (Fig. 4 B).
Therefore, although the suppressive effect of the superna-
tants on naive cells can be partially or completely blocked
by anti–IL-10 and anti–TGF-b, respectively, it appears that
the SEA-treated spleen cells themselves are in a state of un-
responsiveness that cannot be completely reversed by the
addition of these antibodies to the cultures.
On day 20 the SEA-treated spleen cells produce a small
amount of IL-2 on stimulation, but still significantly less than
do the PBS-treated control spleen cells, as measured by
quantitative RT-PCR for the mRNA (Fig. 1 B) as well as
the functional assay (Fig. 1 A). At this time point, no anti-
cytokine antibodies, including anti–TGF-b, had any aug-
menting effect (Fig. 4 B). The level of IL-2 produced at
day 20 is comparable to the amount produced at day 4 or 5
in the presence of anti–TGF-b, and supernatants at day 20
no longer suppress IL-2 production of naive spleen cells
(Fig. 4 A). These results all suggest that the negative effect
of the supernatants has dissipated by day 20 because the
cells are no longer making TGF-b and not much IL-10
(data not shown). Thus, it is possible that another mecha-
nism is responsible for the decreased IL-2 production seen
at this time point. The diminished IL-2 production per cell
at limiting dilution (Fig. 2 A) and the failure to respond
fully to IL-2 despite normal upregulation of IL-2Ra (Fig.
1 C) suggest an intrinsic functional inactivation of the T cell
possibly akin to an anergic state.
SEA-treated Spleen Cells Show a Biochemical Block in ERK
Activation. To more directly examine the possibility that
an anergic mechanism was operating in this system, we looked
at the activation of the mitogen-activated protein (MAP)
kinase pathway after TCR stimulation. Several previous re-
ports have demonstrated a block in ERK activity (29) and
phospho-ERK generation in anergic T cells (30). As shown
in Fig. 5 A, spleen cells from PBS-treated mice showed an
increase in the level of phosphorylation of ERK 1 and 2
that peaked at 15–30 min after anti-CD3 stimulation. No
differences were found in the total amounts of the ERK
proteins after stimulation, demonstrating that only the acti-
vation state of the proteins is altered. In contrast, spleen
Table II. Effect of IL-10 and TGF-b on IL-2 Production by 
Stimulated Naive Spleen Cells
Cytokines added Experiment 1 Experiment 2
U/ml
None 45 150
30 pg/ml TGF-b13 0 9 7
30 pg/ml TGF-b2 25 108
1 ng/ml IL-10 30 114
1 ng/ml IL-10 1
30 pg/ml TGF-b11 5 3 1
1 ng/ml IL-10 1
30 pg/ml TGF-b25 1 7
Day 4 supernatant 0.1 0.4
All cultures contained 105 naive spleen cells plus 5 3 105 T-depleted
spleen cells (APCs), stimulated with 1 mM PCC peptide for 48 h at
37°C. IL-2 was measured by bioassay (CTL-L). Data shown are from
two out of three separate experiments.
Figure 5. ERK activation is di-
minished in spleen cells from SEA-
treated mice.  (A) Time course of
activation for B10.A TCR–Cyt
5C.C7-1 RAG2/2 spleen cells. 7 3
106 cells were incubated on anti-
CD3 (2C11)-coated plates for the indicated times (top). Total ERK pro-
tein levels are shown underneath. (B) ERK activation in PBS- versus
SEA-treated spleen cells. 7 3 106 cells were left unstimulated (U) or stim-
ulated on anti-CD3–coated plates for 15 min (S). Total ERK protein lev-
els are shown underneath. (C) Time course of ERK activation in SEA-
treated spleen cells at day 4 after a third injection with SEA. CD81 T cells
were depleted from both populations giving 55% CD41 cells in the con-
trol and 70% CD41 cells in the SEA-treated spleen. 7 3 106 cells were
incubated on anti-CD3–coated plates for the indicated times (top). Total
ERK protein levels are shown underneath. (D) Time course of ERK acti-
vation in SEA-treated spleen cells at day 20 after a third injection with
SEA. 7 3 106 cells were incubated on anti-CD3–coated plates for the in-
dicated times (top). Total ERK protein levels are shown underneath. (E)
Supernatants from stimulated SEA-treated spleen cells do not diminish
ERK activation in stimulated naive spleen cells. Naive B10.A-TCR–Cyt
5C.C7-1 RAG-22/2 spleen cells were incubated for the indicated times
in the presence of supernatant from stimulated SEA-treated spleen cells at
day 4 after a third injection with SEA. The spleen cells were then stimu-
lated on anti-CD3–coated plates for 15 min in the continued presence of
the supernatant. Total ERK protein levels are shown underneath.61 Miller et al.
cells from SEA-treated mice 20 d after the last in vivo in-
jection showed a significant impairment of ERK activation
by anti-CD3 stimulation (Fig. 5 B). The percentage of CD41
cells at this time was comparable to that found in the PBS
controls, and the percentage of CD81 cells was ,6%. The
decrease in ERK activation did not represent a shift in ki-
netics, as shown in Fig. 5 D. Of the five experiments per-
formed, four showed a 15-fold decrease in relative ERK
activation as quantitated on a PhosphorImager (Molecular
Dynamics), and one experiment showed only a threefold
decrease. These observations support the conclusion that an
anergic state is at least partially responsible for the decrease
in IL-2 production seen at day 20.
An examination of ERK phosphorylation at day 4 also
showed a block in the MAP kinase pathway that was not due
to a shift in kinetics (Fig. 5, B and C). The magnitude of the
inhibition was less than that observed at day 20. For six ex-
periments, the geometric mean decrease in ERK phosphory-
lation was approximately sixfold. In two experiments, the
spleen cells were depleted of CD81 cells and enriched for
CD41 cells to a level greater than that of the PBS controls;
similar results were obtained (Fig. 5 C). This block was not
due to the effect of suppression, which was going on simul-
taneously in these cultures, because supernatants from stimu-
lated, SEA-treated spleen cells did not affect ERK activation
in naive spleen cells when added up to 15 min before stimu-
lation with anti-CD3 antibody (Fig. 5 E). Thus, the results
suggest that on day 4 there are two distinct mechanisms op-
erating to prevent IL-2 production, anergy and suppression.
Discussion
Several groups have previously developed model systems
for peripheral tolerance in which T cells are chronically
stimulated with antigen. In some experiments, transgenic T
cells were transferred into irradiated mice containing the
antigen expressed on other peripheral cells (10, 14). In other
experiments, transgenic T cells were transferred into nor-
mal mice and given a tolerogenic immunization protocol (11,
12). Transferred T cells in these systems express activation
markers, expand, and then become unresponsive in that they
no longer proliferate upon restimulation with antigen. The
properties of these cells have not been well characterized
due to the difficulty of recovering adequate numbers of tol-
erized cells from these systems. In one case (28), Vb TCR
transgenic mice given an injection of Mls-incompatible
spleen cells showed several biochemical changes in the
host’s T cells that suggested that clonal anergy was playing a
role in the tolerance process. However, other investigators,
using a similar Mls incompatibility in a nontransgenic model,
concluded that anergy induction does not play a role in this
system, but rather that the T cells were not activatable be-
cause of the nature of their TCR a chains (4).
Many studies have indicated that regulatory cytokines
may contribute to the overall tolerant state in vivo. A role
for TGF-b in the maintenance of tolerant states has been
shown in a number of animal models. Mice rendered toler-
ant by oral ingestion of antigen develop CD81 regulatory
T cells that express varying amounts of TGF-b1, IL-10,
and IL-4 (32). T cell clones making TGF-b obtained from
these animals can suppress the induction of experimental
autoimmune encephalomyelitis, and administration of anti–
TGF-b1 blocks the effect (22). In another system, injection
of a variety of antigens into the anterior chamber of the eye
induces a systemic alteration in the immune response (23).
This immune deviation can be induced in naive T cells by
adding TGF-b to an in vitro culture system, and can be
blocked on transfer into naive hosts by anti–TGF-b antibody
(32). In yet another model, the induction of colitis by the
transfer of a population of CD45RBhiCD41 T cells to C.B-17
scid mice was prevented by cotransfer with CD45RBloCD41
T cells that produce TGF-b (21). Finally, TGF-b1–deficient
mice develop a severe inflammatory disease in multiple organs
that is characterized by cellular infiltrates and is associated
with an increase in IFN-g and TNF-a production (33, 34).
These studies indicate a role for TGF-b in the negative reg-
ulation of the immune response, possibly by actively sup-
pressing or immune deviating autoreactive T cells.
In recent studies, CD41 (10) and CD81 (14) T cells ren-
dered tolerant in vivo by chronic antigenic stimulation
were shown to express the cytokine IL-10 after restimula-
tion in vitro. The involvement of IL-10 in tolerance has also
been demonstrated in a superantigen model involving mul-
tiple injections of SEA into a Vb transgenic mouse (6). IL-10
production began after the second injection of SEA in vivo
and dominated the response after the third injection. Coin-
jection of anti–IL-10 antibody during the tolerance induc-
tion phase prevented the suppression of the IFN-g, TNF,
and IL-4 responses seen in vivo; however, the inhibition of
the IL-2 response was not affected, even though there was
an inverse correlation between the amounts of IL-2 and IL-10
elicited. Sunstedt and coworkers suggested that anergy might
be responsible for the lack of IL-2 production, based on gel
mobility shift assays in which transcription factors required
for IL-2 gene activation were no longer induced (35). How-
ever, the possibility that other mechanisms were responsi-
ble for these observations was not ruled out. Another blend
of anergy and IL-10 was described for human PBLs in-
duced into an anergic state with anti-CD3 antibody in the
presence of IL-10 (27). In this case, both IL-2 production
and the response to IL-2 were inhibited 10 d after exposure
to the stimulus. However, in subsequent experiments cell
lines of both mouse and human CD41 T cells were gener-
ated by repeated stimulation with peptide antigens in the
presence of IL-10. This protocol resulted in the production
of regulatory cells (Tr1) that could suppress proliferation of
naive cells and prevent colitis in IL-10 gene-deficient mice
(26). These results raised an intriguing question as to the na-
ture of the relationship between the suppression and the an-
ergy: were they in fact separate components of the tolerance?
A similar conundrum arose in our experiments. In our
tolerance model, using a TCR transgenic mouse crossed
onto a RAG-22/2 background and injected three times at
4-d intervals with the superantigen SEA, splenic CD41 T
cells also produced large amounts of IL-10 and significant
amounts of TGF-b when restimulated in culture with anti-62 Anergy and Suppression In Vivo
gen and APCs, although they failed to produce much IL-2,
IL-4, or IFN-g (Table I). Supernatants from these stimu-
lated cells could suppress proliferation and IL-2 production
by naive antigen–specific T cells and this suppression could
be completely blocked by anti–TGF-b and partially blocked
by anti–IL-10. Interestingly, the suppression could not be
fully mimicked with a combination of recombinant IL-10
and TGF-b1 or 2 at any concentrations tested. This obser-
vation suggests that there is a third component required to
give maximum suppression of IL-2 production. IL-10 and
TGF-b alone gave only a 10-fold inhibition, whereas fresh
supernatant inhibited z300–1,000-fold. The antibody block-
ing experiments also suggest that the third component re-
quires IL-10 and TGF-b for the full suppressive effect of the
supernatant to manifest. Future studies will attempt to charac-
terize this new suppressive component and its site of action.
We observed that the suppressive effect wanes with time
after the last injection with SEA in vivo. By day 20, superna-
tants from antigen and APC–stimulated spleen cells were no
longer suppressive, although in direct mixing experiments
the IL-2 production by naive spleen cells could still be inhib-
ited threefold (Fig. 3 A). Stimulated SEA-treated CD41
spleen cells at day 20 did not produce much IL-10 and no
detectable TGF-b (data not shown). Yet such stimulation
yielded only 8% of the IL-2 production seen with PBS-
treated controls (Fig. 1 A) and IL-2 mRNA levels 24 h after
stimulation were decreased 100-fold (Fig. 1 B). This was ac-
companied by a decrease in the amount of IL-2 produced
per cell, even though the decreased frequency of IL-2–
producing cells observed at day 4 had returned to normal by
day 20 (Fig. 2). Finally, antibodies against a variety of cyto-
kines, including TGF-b or IL-10, had no augmenting effect.
These results suggest that the inhibition of IL-2 production
on day 20 is not due to these two immunosuppressive cyto-
kines, although a small contribution by the unknown third
component has not been ruled out definitively.
Instead, we think that the unresponsiveness at day 20 is
due to a state of clonal anergy. Several pieces of data argue
in favor of this idea. One is the decreased amount of IL-2
produced per cell, which at day 20 is z60% of control lev-
els. The second is the decrease in ERK activation after
stimulation with anti-CD3 antibody. This demonstrates that
the Ras/MAP kinase pathway is blocked in these cells.
Third, the proliferative response of these cells is suboptimal
and could not be augmented by the addition of exogenous
IL-2. The upregulation of IL-2Ra chain was normal, but
signaling through the receptor was somehow blocked. Al-
though classical murine clonal anergy does not involve a
loss of IL-2 responsiveness, because the long-term T cell
clones abnormally constitutively express high affinity IL-2
receptors, anergy induction of naive T cells in vivo (28) or in
vitro (29) have shown that this can occur. Thus, the individ-
ual T cells appear to be functionally impaired in a number of
ways at day 20. In a few experiments, the degree of impair-
ment was noticeably less than in all the others, e.g., experi-
ment 2 in Fig. 2, A and C, and in one ERK activation assay.
This occasional discrepancy could be due to the emergence
of new naive cells from the thymus that are diluting out the
anergic population of cells. Experiments with thymecto-
mized mice are planned to explore this possibility.
The question of whether anergic cells are also present at
day 4 was more difficult to ascertain. The original experi-
ments of Sundstedt et al. used electrophoretic mobility shift
assays to look at activation of transcription factors (35). Al-
though they found that SEA-treated cells showed decreased
binding of the AP-1 transcription factor, as described for an-
ergic T cell clones (36), they also found complete inhibition
of binding of both the nuclear factor of activated T cells
and the p65/p55 form of the nuclear factor kB transcrip-
tion factors to IL-2 enhancer sites. This could represent a
more profound form of anergy. However, because we know
from our work that there is also a suppressive component
contributing to the unresponsiveness at that point in time,
it is not clear whether the observed effects on IL-2 produc-
tion were all due to anergy. To circumvent this problem,
we carried out three assays that we thought might be inde-
pendent of the suppressive component. One was the limit-
ing dilution analysis that showed that the IL-2 production
per cell was decreased to 40% of normal. This demonstrates
that at least a component of the unresponsiveness at day 4 is
an intrinsic property of the CD41 T cell. However, if this
cell is also making the suppressive molecules, then it might
be suppressing itself in an autocrine fashion. A more defini-
tive experiment was the assay for activation of the ERK ki-
nases after TCR stimulation. We showed that the suppres-
sive components in the supernatant could not block this
activation pathway and yet day 4, SEA-treated spleen cells
showed a sixfold reduction in ERK activation. In addition,
anti–TGF-b treatment of activated day 4, SEA-treated
spleen cells improved the IL-2 production of these cells by
only 10-fold, leaving a 30-fold deficit due to something else.
These results strongly suggest that, even at day 4, there is an
underlying anergic component contributing to the defect in
IL-2 production and that the profoundness of the deficit seen
at that time is due to a combination of an anergic effect and
the suppression mediated by IL-10, TGF-b, and an unknown
factor(s). It will be interesting in future experiments to deter-
mine whether the unusual pattern of transcription factor
blockade seen by Sundstedt et al. is mediated by this unique
combination of the two tolerance mechanisms.
An important question, which we have not addressed in
this paper, is whether these two mechanisms for preventing
IL-2 production, anergy, and suppression, are functionally
independent. Murine anergic T cell clones do not make
much IL-10 upon stimulation, nor do the unresponsive cells
found at day 20 after SEA treatment in vivo (data not
shown). Nonetheless, Groux et al. have shown that stimu-
lation of human naive T cells in the presence of IL-10 can
facilitate the induction of an anergic-like state. Thus, the
possibility remains that production of IL-10, TGF-b, and
other suppressive molecules contribute to the induction of
the anergic state seen following three rounds of in vivo
treatment with superantigen. The model system we have
described in this paper should allow us to address this issue
directly by following the biochemical events as they occur
both in vivo and in vitro.63 Miller et al.
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